Abstract
It is estimated in Brazil that more than 2 million people have Chronic Kidney Disease (CKD) at different stages and approximately 100,000 patients are in renal replacement therapy. However, therapeutic strategies to control the progression of CKD are limited to the control of basal diseases and the use of drugs that block the renin-angiotensin system. Thus there is an avid need for new ag…